期刊
JOURNAL OF HOSPITAL INFECTION
卷 107, 期 -, 页码 35-39出版社
W B SAUNDERS CO LTD
DOI: 10.1016/j.jhin.2020.09.035
关键词
COVID-19; SARS-CoV-2; Rapid diagnostics
资金
- Agency for Healthcare Research and Quality Connected Emergency Care Patient Safety Learning Lab [R18 HS26640]
- Biomedical Advanced Research and Development Authority BARDA [IDSEP150023-01-00]
- Centers for Disease Control, Modeling in Infectious Disease Network [U01CK000536]
- National Institute of Allergy and Infectious Diseases [HHSN272201400007C]
Rapid molecular testing for SARS-CoV-2 can significantly reduce the time to diagnosis of COVID-19, decrease healthcare-related exposure, conserve infection control resources, and increase treatment capacity.
Opportunity exists to decrease healthcare-related exposure to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), preserve infection control resources, and increase care capacity by reducing the time to diagnosis of coronavirus disease 2019 (COVID-19). A retrospective cohort analysis was undertaken to measure the effect of targeted rapid molecular testing for SARS-CoV-2 on these outcomes. In comparison with standard platform testing, rapid testing was associated with a 65.6% reduction (12.6 h) in the median time to removal from the isolation cohort for patients with negative diagnostic results. This translated to an increase in COVID-19 treatment capacity of 3028 bed-hours and 7500 fewer patient interactions that required the use of personal protective equipment per week. (C) 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据